Evy Lundgren Åkerlund, Ph.D., CEO 

Oct. 13 | 10:00am | Oxford Biomedica Ballroom 

Lund, Sweden 


In-person Presentation 

Xintela is a clinical-stage biopharmaceutical company developing allogeneic mesenchymal stem cell (MSC)-based therapies with a current focus on osteoarthritis (OA) and difficult-to-heal venous leg ulcers (VLU). The company’s proprietary product platform XSTEM® is based on integrin α10β1-selected MSCs which assures homogenous and high quality MSC preparations and consistency between donors. XSTEM is manufactured in Xintela’s own GMP-approved facility. Xintela has started a Phase I/IIa clinical study with XSTEM for the treatment of knee OA and will start a Phase I/IIa clinical study for the treatment of VLU in Q3 2022. The goal is to show that XSTEM is safe and to investigate preliminary efficacy. Preclinical studies in large animals have demonstrated both safety and regenerative properties of integrin α10β1-selected MSCs and support the disease-modifying effect of XSTEM. Xintela’s current XSTEM pipeline also includes treatment of ARDS as well as MSC products for the treatment of degenerative joint diseases in animals.

By using this website you agree to accept our Privacy Policy and Terms & Conditions